Drug intelligence / Profile preview

adenovirus-transfected autologous dendritic cell vaccine + cytokine-induced killer cells

Development stage
Unknown
Lead developer
307 Hospital of the People's Liberation Army
Modality
Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
Administration
Subcutaneous, Intravenous
01

Overview

A combination immunotherapy approach consisting of autologous dendritic cells (DCs) that have been genetically modified using adenoviral vectors to express tumor-associated antigens (such as MART-1, p53, MUC1, or Survivin), combined with cytokine-induced killer (CIK) cells. The DC vaccine component presents tumor antigens to activate specific T cell responses, while CIK cells provide direct tumor-killing activity through both MHC-restricted and non-MHC-restricted mechanisms. This dual approach aims to enhance overall anti-tumor efficacy compared to either component alone.

Other names
DC-CIKgmDCs-CIKdendritic cell-cytokine-induced killer cell therapy

Beyond the preview

Go deeper on adenovirus-transfected autologous dendritic cell vaccine + cytokine-induced killer cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on adenovirus-transfected autologous dendritic cell vaccine + cytokine-induced killer cells.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call